Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study

DOI: 10.1016/s2213-2600(16)30307-1
Lancet Respiratory Medicine,the, 2016, 4, 894-901.

#	Paper	IF	Citations
52	Time to consider death in clinical trials for PAH. *Lancet Respiratory Medicine,the*, **2016**, 4, 849-850	35.1	1
51	Ambrisentan: a review of its use in pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2017**, 11, 233-244	4.9	12
50	Pulmonary Hypertension-Back to the Future. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 901-904	3.7	1
49	Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?. *Internal Medicine Journal*, **2017**, 47, 1124-1128	1.6	
48	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. *Pulmonary Circulation*, **2017**, 7, 312-325	2.7	35
47	Hipertensiâ pulmonar. Regreso al futuro. *Revista Espanola De Cardiologia*, **2017**, 70, 901-904	1.5	2
46	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. *ClinicoEconomics and Outcomes Research*, **2017**, 9, 731-739	1.7	13
45	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 860-868	10.2	27
44	Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. *Heart Lung and Circulation*, **2018**, 27, 1368-1375	1.8	17
43	Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. *Current Medical Research and Opinion*, **2018**, 34, 263-273	2.5	5
42	Room With a View. *Circulation: Cardiovascular Imaging*, **2018**, 11, e008148	3.9	1
41	Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. *Vascular Health and Risk Management*, **2018**, 14, 253-264	4.4	20
40	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. *International Journal of Cardiology*, **2018**, 272S, 37-45	3.2	33
39	Ambrisentan tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. *Drugs and Therapy Perspectives*, **2018**, 34, 289-299	1.5	
38	Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1090-1093	10.2	2
37	Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. *Journal of Cardiology*, **2018**, 72, 466-472	3	24
36	Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. *Pediatric Pulmonology*, **2019**, 54, 1516-1526	3.5	11

35	Selexipag in the management of pulmonary arterial hypertension: an update. *Drug, Healthcare and Patient Safety*, **2019**, 11, 55-64	1.6	3
34	Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice. *Circulation Reports*, **2019**, 1, 268-275	0.7	1
33	Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. *American Journal of Cardiovascular Drugs*, **2019**, 19, 99-105	4	5
32	A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects. *Clinical Therapeutics*, **2019**, 41, 1110-1127	3.5	1
31	Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines.. *Journal of Scleroderma and Related Disorders*, **2019**, 4, 35-42	2.3	9
30	Survival Improved in Patients Aged ≥70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. *Chest*, **2020**, 157, 945-954	5.3	5
29	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 707-717	10.2	40
28	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. **2020**, 11, 1623-1639		9
27	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. *Annals of the Rheumatic Diseases*, **2020**, 79, 626-634	2.4	11
26	Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 614-627	10.2	10
25	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. *Expert Review of Respiratory Medicine*, **2021**, 15, 493-504	3.8	2
24	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 842-854	10.2	13
23	Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis. *Journal of Clinical Pharmacy and Therapeutics*, **2021**,	2.2	3
22	Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. *EPMA Journal*, **2021**, 12, 1-41	8.8	14
21	Advances in the management of pulmonary arterial hypertension. *Journal of Investigative Medicine*, **2021**, 69, 1270-1280	2.9	4
20	How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. *Journal of Cardiothoracic and Vascular Anesthesia*, **2021**,	2.1	0
19	New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine. *Physiological Research*, **2018**, 67, S37-S54	2.1	14
18	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. *European Respiratory Journal*, **2021**,	13.6	6

17	Mortality trends in pulmonary arterial hypertension in canada: a temporal analysis of survival per ESC/ERS Guideline Era. *European Respiratory Journal*, **2021**,	13.6	6
16	Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape. *Advances in Pulmonary Hypertension*, **2017**, 15, 193-197	0.5	
15	Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.. *International Heart Journal*, **2022**, 63, 99-105	1.8	
14	The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study.. *Frontiers in Pharmacology*, **2021**, 12, 811700	5.6	0
13	Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension STAT3/HIF-1/VEGF and FAK/AKT Signaling Pathways.. *Frontiers in Pharmacology*, **2022**, 13, 844400	5.6	2
12	Transdisciplinary Imagination: Addressing Equity and Mistreatment in Perinatal Care.. *Maternal and Child Health Journal*, **2022**,	2.4	
11	To be or not to be treated with initial combination therapy, that is the (PAH) question. *European Respiratory Journal*, **2022**, 59, 2200390	13.6	
10	Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. *ESC Heart Failure*,	3.7	0
9	Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension. *Open Heart*, **2022**, 9, e002054	3	
8	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
7	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
6	Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2022**, 146, 597-612		0
5	Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients. 9,		0
4	Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. 9,		0
3	Portopulmonary Hypertension Rethinking Our Current Approach. **2022**, 97, 2189-2191		0
2	Pathophysiology and new advances in pulmonary hypertension. **2023**, 2, e000137		0
1	The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease. **2023**, 108418		0